No edit summary |
|||
| Line 29: | Line 29: | ||
*ENDS = Electronic Nicotine Delivery System | *ENDS = Electronic Nicotine Delivery System | ||
*NVP = Nicotine Vapor Product | *NVP = Nicotine Vapor Product | ||
===2021 [https://onlinelibrary.wiley.com/doi/10.1111/add.15403 Dependence on nicotine in US high school students in the context of changing patterns of tobacco product use]=== | |||
*Among US high school students, increases in the prevalence of nicotine product use from 2012 to 2019 do not appear to have been accompanied by a similar increase in the population burden of nicotine dependence. This may be at least partly attributable to a shift in the most common product of choice from cigarettes (on which users are most dependent) to e-cigarettes (on which users are least dependent). | |||
*[https://onlinelibrary.wiley.com/doi/epdf/10.1111/add.15403 PDF Version] | |||
*Citation: Jackson, S. E., Brown, J., and Jarvis, M. J. (2021) Dependence on nicotine in US high school students in the context of changing patterns of tobacco product use. Addiction, 116: 1859– 1870. doi: 10.1111/add.15403 | |||
*Acknowledgement: Cancer Research UK (C1417/A22962) supported S.J. andJ.B.’s salaries. | |||
===2020 [https://pubmed.ncbi.nlm.nih.gov/33176942/ Abuse liability assessment of the JUUL system in four flavors relative to combustible cigarette, nicotine gum and a comparator electronic nicotine delivery system among adult smokers]=== | ===2020 [https://pubmed.ncbi.nlm.nih.gov/33176942/ Abuse liability assessment of the JUUL system in four flavors relative to combustible cigarette, nicotine gum and a comparator electronic nicotine delivery system among adult smokers]=== | ||
| Line 40: | Line 46: | ||
===2020 [https://www.tandfonline.com/doi/abs/10.1080/10826084.2020.1834582?journalCode=isum20& Dependence and Use Characteristics of Adult JUUL Electronic Cigarette Users]=== | ===2020 [https://www.tandfonline.com/doi/abs/10.1080/10826084.2020.1834582?journalCode=isum20& Dependence and Use Characteristics of Adult JUUL Electronic Cigarette Users]=== | ||
* | * | ||
===2020 [https://pubmed.ncbi.nlm.nih.gov/33086157/ A comparison of product dependence among cigarette only, ENDS only, and dual users: Findings from Wave 3 (2015-2016) of the PATH study]=== | ===2020 [https://pubmed.ncbi.nlm.nih.gov/33086157/ A comparison of product dependence among cigarette only, ENDS only, and dual users: Findings from Wave 3 (2015-2016) of the PATH study]=== | ||
| Line 65: | Line 58: | ||
*Citation: Goldenson NI, Buchhalter AR, Augustson EM, Rubinstein ML, Henningfield JE. Abuse liability assessment of the JUUL system in four flavors relative to combustible cigarette, nicotine gum and a comparator electronic nicotine delivery system among adult smokers. Drug Alcohol Depend. 2020 Dec 1;217:108395. doi: 10.1016/j.drugalcdep.2020.108395. Epub 2020 Nov 4. PMID: 33176942. | *Citation: Goldenson NI, Buchhalter AR, Augustson EM, Rubinstein ML, Henningfield JE. Abuse liability assessment of the JUUL system in four flavors relative to combustible cigarette, nicotine gum and a comparator electronic nicotine delivery system among adult smokers. Drug Alcohol Depend. 2020 Dec 1;217:108395. doi: 10.1016/j.drugalcdep.2020.108395. Epub 2020 Nov 4. PMID: 33176942. | ||
*Acknowledgment: The study was funded by Juul Labs, Inc. NIG, EMA and MLR are full-time employees of Juul Labs, Inc., JEH and ARB are full-time employees of PinneyAssociates, Inc. PinneyAssociates provides consulting services on tobacco harm reduction on an exclusive basis to Juul Labs, Inc. Within the last two years, PinneyAssociates has consulted for British American Tobacco and Reynolds American Inc and subsidiaries on tobacco harm reduction. JEH co-holds a patent for a novel nicotine medication that has not been developed or commercialized. There are no other interests declared by authors. | *Acknowledgment: The study was funded by Juul Labs, Inc. NIG, EMA and MLR are full-time employees of Juul Labs, Inc., JEH and ARB are full-time employees of PinneyAssociates, Inc. PinneyAssociates provides consulting services on tobacco harm reduction on an exclusive basis to Juul Labs, Inc. Within the last two years, PinneyAssociates has consulted for British American Tobacco and Reynolds American Inc and subsidiaries on tobacco harm reduction. JEH co-holds a patent for a novel nicotine medication that has not been developed or commercialized. There are no other interests declared by authors. | ||
===2019 [https://pubmed.ncbi.nlm.nih.gov/31375364/ Changes in E-Cigarette Use Behaviors and Dependence in Long-term E-Cigarette Users]=== | |||
* | |||
===2018 [https://pubmed.ncbi.nlm.nih.gov/29725702/ Assessment of the abuse liability of three menthol Vuse Solo electronic cigarettes relative to combustible cigarettes and nicotine gum]=== | ===2018 [https://pubmed.ncbi.nlm.nih.gov/29725702/ Assessment of the abuse liability of three menthol Vuse Solo electronic cigarettes relative to combustible cigarettes and nicotine gum]=== | ||
| Line 73: | Line 69: | ||
===2017 [https://pubmed.ncbi.nlm.nih.gov/28389330/ A comparison of nicotine dependence among exclusive E-cigarette and cigarette users in the PATH study]=== | ===2017 [https://pubmed.ncbi.nlm.nih.gov/28389330/ A comparison of nicotine dependence among exclusive E-cigarette and cigarette users in the PATH study]=== | ||
* | |||
===2015 [https://pubmed.ncbi.nlm.nih.gov/25332459/ Development of a questionnaire for assessing dependence on electronic cigarettes among a large sample of ex-smoking E-cigarette users]=== | |||
* | * | ||
| Line 91: | Line 90: | ||
='''Nicotine Replacement Therapy (NRT)'''= | ='''Nicotine Replacement Therapy (NRT)'''= | ||
===2020 [https://pubmed.ncbi.nlm.nih.gov/33176942/ Abuse liability assessment of the JUUL system in four flavors relative to combustible cigarette, nicotine gum and a comparator electronic nicotine delivery system among adult smokers]=== | |||
*Conclusions: Controlled use of JS among adult smokers resulted in nicotine delivery, product liking, and satisfaction that were less than that of combustible cigarettes but generally greater than nicotine gum. These results support the conclusion that JS has lower abuse liability than combustible cigarettes, higher abuse liability than nicotine gum, and may provide sufficient nicotine delivery and satisfying effects to support substitution for combustible cigarettes among adult smokers. | |||
*Citation: Goldenson NI, Buchhalter AR, Augustson EM, Rubinstein ML, Henningfield JE. Abuse liability assessment of the JUUL system in four flavors relative to combustible cigarette, nicotine gum and a comparator electronic nicotine delivery system among adult smokers. Drug Alcohol Depend. 2020 Dec 1;217:108395. doi: 10.1016/j.drugalcdep.2020.108395. Epub 2020 Nov 4. PMID: 33176942. | |||
*Acknowledgment: The study was funded by Juul Labs, Inc. NIG, EMA and MLR are full-time employees of Juul Labs, Inc., JEH and ARB are full-time employees of PinneyAssociates, Inc. PinneyAssociates provides consulting services on tobacco harm reduction on an exclusive basis to Juul Labs, Inc. Within the last two years, PinneyAssociates has consulted for British American Tobacco and Reynolds American Inc and subsidiaries on tobacco harm reduction. JEH co-holds a patent for a novel nicotine medication that has not been developed or commercialized. There are no other interests declared by authors. | |||
===2018 [https://pubmed.ncbi.nlm.nih.gov/29725702/ Assessment of the abuse liability of three menthol Vuse Solo electronic cigarettes relative to combustible cigarettes and nicotine gum]=== | |||
*These findings are concordant with our previous results and provide evidence that menthol Vuse Solo ECs have abuse liability that is lower than menthol cigarettes and potentially greater than that of nicotine gum. | |||
*[https://sci-hub.se/10.1007/s00213-018-4904-x PDF Version] | |||
*Citation: Stiles MF, Campbell LR, Jin T, Graff DW, Fant RV, Henningfield JE. Assessment of the abuse liability of three menthol Vuse Solo electronic cigarettes relative to combustible cigarettes and nicotine gum. Psychopharmacology (Berl). 2018 Jul;235(7):2077-2086. doi: 10.1007/s00213-018-4904-x. Epub 2018 May 3. PMID: 29725702; PMCID: PMC6015619. | |||
*Acknowledgement: ClinicalTrials.gov identifier: NCT02664012. MF Stiles, LR Campbell, and T Jin are full-time employees of RAI Services Company. RAI Services Company is a wholly owned subsidiary of Reynolds American Inc., which is a wholly owned subsidiary of British American Tobacco plc. DW Graff is a full-time employee of Celerion and provided the original draft of the manuscript. RV Fant and JE Henningfield are full-time employees of PinneyAssociates, which provides consulting services on smoking cessation and tobacco harm minimization (including nicotine replacement therapy and electronic vapor products) to Niconovum, USA, Inc., RJ Reynolds Vapor Company, and RAI Services Company (all subsidiaries of Reynolds American Inc.). JE Henningfield also owns an interest in intellectual property for a novel nicotine medication. Through PinneyAssociates, Fant and Henningfield provide consulting services to pharmaceutical companies on abuse potential assessment, and the regulation of substances with a potential for abuse. | |||
===2015 [https://pubmed.ncbi.nlm.nih.gov/25561385/ Dependence levels in users of electronic cigarettes, nicotine gums and tobacco cigarettes]=== | |||
* | |||
===2013 [https://www.federalregister.gov/documents/2013/04/02/2013-07528/modifications-to-labeling-of-nicotine-replacement-therapy-products-for-over-the-counter-human-use Modifications To Labeling of Nicotine Replacement Therapy Products for Over-the-Counter Human Use]=== | ===2013 [https://www.federalregister.gov/documents/2013/04/02/2013-07528/modifications-to-labeling-of-nicotine-replacement-therapy-products-for-over-the-counter-human-use Modifications To Labeling of Nicotine Replacement Therapy Products for Over-the-Counter Human Use]=== | ||
edits